ABSTRACT: The objective of this study was to validate subcutaneous (sc) microdialysis sampling to study¯urbiprofen pharmacokinetics and plasma protein binding in the awake freely moving rat. A linear microdialysis probe was manufactured using a Hemophane 1 hollow ®ber which was tested in vitro and in vivo for the recovery of urbiprofen and naproxen used as retrodialysis marker. Flurbiprofen was administered intraperitoneally and intravenously at a dose of 20 mg/kg in rats. In both cases, conventional blood sampling and sc microdialysis sampling were simultaneously performed. The microdialysates were analyzed on-line by high-pressure liquid chromatography. Naproxen, which was shown to have a similar in vivo loss by retrodialysis as¯urbiprofen (71.5 AE 0.9% and 71.0 AE 0.8% respectively, n 3), was used to continuously monitor probe recovery. Concentration-dependent protein binding of urbiprofen was demonstrated in vivo based on experiments with a simultaneous sc microdialysis and blood sampling. Values of unbound fraction were similar to those reported previously by intravenous microdialysis sampling, demonstrating that the sc unbound concentrations are very similar to those in the central compartment. There was no signi®cant difference among pharmacokinetic parameters (AUC, CL, t 1/2z , Vd) for total or unbound¯urbiprofen determined after intraperitoneal and intravenous administration. Subcutaneous microdialysis is a simple yet powerful tool to study the pharmacokinetics and the in vivo plasma protein binding of¯urbiprofen in the awake unrestrained rat. ß
INTRODUCTION
The principle of the microdialysis technique is based on the passive diffusion of compounds down a concentration gradient across the semipermeable membrane of a dialysis ®ber. In function of the direction of the concentration gradient across the ®ber, the microdialysis technique may be used not only to monitor the extracellular concentrations of exogenous or endogenous compounds but may also be used to deliver drugs to a speci®c region of the body. Important advantages of microdialysis are: 1. increased sampling frequency to characterize the concentration±time pro®le with a discriminating resolution, 2. reduction of the number of experimental animals, 3. because the dialysis ®ber prevents diffusion of proteins, samples are suf®ciently puri®ed for further analysis, and 4. possibility to study pharmacokinetics in awake freely moving animals in almost real time by on-line analysis of microdialysates by using various techniques. Originally developed and applied in brain research, 1 microdialysis has become during the last decade a common sampling method in conventional pharmacokinetic studies. Microdialysis sampling is a powerful tool to continuously monitor the extracellular unbound drug concentrations in different``compartments'' of the body. Indeed, microdialysis probes can be implanted in virtually any body organ or tissue.
2±5
Only a few articles are published describing the application of subcutaneous (sc) microdialysis sampling to study the pharmacokinetics of drugs in rats 6, 7 or in humans. 8, 9 Subcutaneous tissue is an attractive sampling site for several reasons: 1. this tissue is relatively uniform, 2. the extracellular¯uid is in constant¯ux with the systemic circulation, and 3. the implantation of the probe in sc tissue is easy. 7 Despite these interesting characteristics, no data are reported in the literature regarding the use of sc microdialysis sampling to study the pharmacokinetics of drugs with a very high plasma protein binding in the awake freely moving rat.
The purpose of the present study was to validate the sc microdialysis sampling technique to investigate the pharmacokinetics of a highly plasma protein bound drug such as¯urbiprofen. First, the recovery of a simple linear microdialysis probe was determined in vitro and in vivo by using naproxen as retrodialysis marker. 10, 11 Subsequently, the ability of sc microdialysis sampling to measure unbound concentrations of¯urbipro-fen was demonstrated by studying the pharmacokinetics of this drug after intraperitoneal (ip) or intravenous (iv) administration with simultaneous conventional blood sampling. Finally, based on the results of the in vivo experiments with simultaneous microdialysis and blood sampling, concentration-dependent plasma binding of urbiprofen was demonstrated.
EXPERIMENTAL Materials
Flurbiprofen and naproxen were purchased from Sigma Chemical Co. (St. Louis, MO). Solvents were high-pressure liquid chromatography (HPLC) grade and all other chemicals used were AR grade. Hairless male rats (Iffa Credo, Saint-Germain, France), weighing between 280 and 350 g, were used. Food (type A04; U.A.R., Epinay-sur-Orge, France) and tap water were provided ad libitum.
Surgical Procedure
Rats were anesthetized with a mixture of 4 mg/kg droperidol and 0.08 mg/kg fentanyl (Thalamonal 1 ; Janssen Pharmaceutica, Beerse, Belgium). Cannulae of silastic tubing [0.94 mm outside diameter (o.d.), 0.51 mm inside diameter (i.d.); Dow Corning, Valbonne, France] were implanted in the right and left jugular vein using standard surgical procedures. The animals were allowed to recover from the surgery overnight. The described experimental procedures in the rats were approved by the University Animal Experimentation Ethics Committee.
Microdialysis Probe
The linear microdialysis probes were manufactured using a Hemophane 1 dialysis ®ber (210 mm i.d.; Gambro AB, Lund, Sweden) with a molecular weight cut-off of 5000 Da. The ®ber (20 mm length) was glued at both ends to a piece of silicone tubing (0.012 in. i.d., 0.025 in. o.d.; Specialty Manufacturing Inc., Saginaw, MI) using B-210 cyanoacrylate glue (3M, Brussels, Belgium).
In Vitro and In Vivo Evaluation of the Recovery of the Probe
To characterize the dialysis ef®ciency of the probes, relative recoveries for¯urbiprofen and naproxen (retrodialysis marker) were determined in vitro. The probes were placed in glass beakers at 378C containing different concentrations of urbiprofen or naproxen and perfused with an isotonic phosphate buffer pH 7.4 [phosphate buffered saline (PBS) Na 2 HPO 4 3.191 g/L; NaH 2 PO 4 0.775 g/L, NaCl 5.58 g/L] at 2 mL/min. Analyte concentrations were measured in the dialysate and expressed as a percentage of the concentration in the surrounding medium.
In vivo recovery was determined by the retrodialysis method or``internal reference technique'' 12,13 which consists of adding a retrodialysis marker to the perfusate and measuring the rate of delivery of this compound. This in vivo calibration method relies on the assumption that the recovery of the analyte is quantitatively the same as the delivery of the retrodialysis marker. After implantation of the probe in sc tissue, the probe was perfused at a¯ow rate of 2 mL/min with PBS pH 7.4 containing¯urbiprofen (250 ng/mL) or naproxen (250 ng/mL). Analyte concentrations were measured in the microdialysate samples (C out ) every 10 min for 8 h. The recovery was determined from the ratio of the concentration lost to the initial concentration in the perfusate (C in ):
Implantation of the Microdialysis Probe in the Rat and Microdialysis System
The probe implantation was performed as follows. The animals were anesthetized with a mixture of 4 mg/kg droperidol and 0.08 mg/kg fentanyl injected subcutaneously. The skin of the dorsal region was punctured horizontally by a 20-gauge iv plastic cannula. The steel mandrel was removed and the microdialysis probe was inserted subsequently. The plastic cannula was withdrawn, leaving the probe in the sc tissue. The probe was sutured to the skin to secure it. Then the rat was placed in a freely awake moving system of microdialysis (CMA/120, Stockholm, Sweden) for the duration of the experiment. The rat had free access to food and water during the microdialysis sampling period.
The probe inlet and outlet were connected to a dual channel swivel (Instech Laboratories Inc., Plymouth, PA) using PEEK 1 tubing (0.65 mm o.d. Â 0.12 mm i.d.; CMA). The inlet of the swivel was then connected to a syringe pump (CMA/100) while the outlet was linked to an on-line injector (CMA/160). The probe was perfused with PBS pH 7.4 containing naproxen (250 ng/mL) as retrodialysis marker at a¯ow of 2 mL/min during the pharmacokinetic experiment.
Probe Depth Measurement
To evaluate the sc implantation procedure, the probe depth was measured by 20 MHz ultrasound scanning using a Dermascan-C instrument (Philips; Philips Research Laboratories, Eindhoven, Holland). Five probes were implanted in rats and the depth measurement was performed at the half distance of the probe under the skin.
In Vitro Plasma Protein Binding of Flurbiprofen
The unbound fraction of¯urbiprofen in plasma was determined in vitro by equilibrium dialysis (Dianorm, Mu È nich, Germany). Blank blood was collected in heparinized tubes by cardiac puncture and immediately centrifuged. Plasma of different rats was pooled and subsequently spiked with urbiprofen to obtain the following concentrations: 0, 5, 10, 20, 40, and 60 mg/mL. These plasma samples were dialyzed in duplicate for 4 h at 378C against PBS pH 7.4 in 1 mL Te¯on dialysis cells using semipermeable membranes with a 6000± 8000 MW cut-off (Spectra/Por 1 1; Spectrum Laboratories Inc., Los Angeles, CA). Plasma albumin concentrations were determined before and after dialysis by the bromocresol dye binding method (Sigma Diagnostics) and used to correct the unbound fraction for volume shifts.
14 Flurbiprofen concentrations in plasma and buffer were determined by HPLC with¯uorescence detection. 
On-line Analysis of Microdialysate Samples by HPLC
The chromatographic system consisted of a highpressure liquid chromatographic pump (model 420; Kontron Instruments, Milan, Italy), an online injector with a 10-port injection valve (CMA/ 160), a programmable¯uorescence detector (SpectraSystem FL2000; Spectra-Physics, San Jose, CA), and a Varian model 4290 integrator (Varian Instruments, Walnut Creek, CA). The microdialysate samples were collected directly in the 10.5 mL PEEK injection loop (Bioanalytical Systems, Inc., Congleton, Cheshire, UK) and automatically injected every 10 min onto a C 18 Nucleosil column (100 Â 4 mm, 5 m; MachereyNagel, Du È ren, Germany). The mobile phase consisted of phosphate buffer 50 mM (pH 3.0) and acetonitrile (54:46, v/v) and was delivered at 0.850 mL/min. The eluate was monitored using the following excitation (ex) and emission (em) wavelengths: 262 nm (ex) and 356 nm (em) from 0±4 min (naproxen), and 258 nm (ex) and 310 (em) from 4±10 min (¯urbiprofen). The lower limit of detection and the lower limit of quanti®-cation were respectively 2.5 and 7 ng/mL.
HPLC Assay of Plasma Samples
Concentrations of¯urbiprofen in plasma were determined by using an HPLC method. 15, 16 To 50 mL of plasma was added 1400 mL of methanol containing 3 mg naproxen/mL (internal standard). After vortexing, the mixture was centrifuged, and 50 mL of supernatant was injected on the HPLC system using a 10 mL sample loop. The HPLC system consisted of an HPLC pump (model 501, Waters Associates, Inc., Milford, MA), an autosampler (Gilson model 231, Villers-le-Bel, France) equipped with a 500 mL syringe, a UV detector (model 481; Waters Associates), and an LDC/ Milton Roy CI-10B integrator (LDC Milton Roy, Riviera Beach, FL). The HPLC column and the chromatographic conditions were the same as described for the on-line analysis of microdialysate samples. The eluate was monitored at 254 nm. The lower limit of detection and the lower limit of quanti®cation were respectively 0.1 and 0.25 mg/mL.
Pharmacokinetic Studies
To evaluate the ability of sc microdialysis to measure the unbound concentrations of¯urbi-profen, a ®rst study after ip administration (20 mg/kg) with simultaneous sc microdialysis and serial blood sampling was performed in four rats. A second study by sc microdialysis sampling with simultaneous serial blood sampling after iv bolus (20 mg/kg) was performed in ®ve rats.
In all pharmacokinetic studies, after implantation of the probe and before the administration of urbiprofen, a period of 90±120 min was required to stabilize the skin blood¯ow which may have been perturbed by the insertion of the steel mandrel during the implantation procedure. 17 After ip and iv administration of¯urbiprofen, the microdialysates and blood samples were collected for a total duration of 6 to 8 h. Blood samples (250 mL) were collected in syringes containing heparin at the following times: 0 (blank), 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, and 480 min. Blood samples were immediately centrifuged and the plasma was stored at À208C until analysis.
Data Analysis
Pharmacokinetic parameters were determined by the so-called``noncompartmental'' approach. AUC values were calculated using the linear trapezoidal rule from 0 to t (last microdialysate or blood sampling time) with extrapolation to in®nity (plasma concentration at time t divided by slope l z ). Terminal dialysate or plasma half-time (t 1/2z ) was calculated as 0.693/l z where l z is estimated by linear regression of the terminal log-linear phase of the dialysate or plasma concentration± time curve. Bioavailability (F) was determined from the ratio of the AUC value after ip administration to the AUC value after iv bolus. Clearance (CL) and the apparent volume of distribution (Vd) were calculated with standard pharmacokinetic equations. 18 Based on unbound concentrations determined in vivo by microdialysis and blood sampling experiments, the binding of¯urbiprofen was analyzed in terms of a one binding site model with or without a linear non-saturable term using the nonlinear least squares regression program WinNonlin 1.5 (Pharsight Corporation, London, U.K.): 
RESULTS AND DISCUSSION
On-line Analysis of Microdialysate Samples by HPLC By preventing the diffusion of proteins into the dialysate, microdialysis provides relatively puri®ed samples free from proteins and cellular matter and which therefore do not require further sample preparation. Thus, chromatograms of microdialysate samples injected directly into the HPLC system contained no interfering sub-stances. Retention times are short (3.0 min for naproxen and 4.7 min for¯urbiprofen) allowing on-line injection at 10 min intervals (data not shown).
In Vitro Calibration of the Microdialysis Probe
A microdialysis probe with a simple linear design was developed with a dialysis ®ber being derived from an arti®cial kidney. The length of the membrane was selected in order to obtain a high recovery of the analyte while allowing an easy implantation. To characterize the dialysis ef®-ciency of the probes and to validate the choice of naproxen as internal standard for the retrodialysis method, in vitro relative recovery of urbiprofen and naproxen was estimated. Mean in vitro recoveries were 74.0 AE 1.1% for¯urbipro-fen (with four probes) and 76.9 AE 0.4% for naproxen (with three probes) ( Table 1 ). In vitro recoveries of naproxen and¯urbiprofen were signi®cantly different (p 0.02). The linear relationship (R 2 0.998) between the concentration in a surrounding solution and in the dialysate over a wide concentration range for both analytes shows that the diffusion through the membrane is independent of the¯urbiprofen or naproxen concentration (Fig. 1) .
Probe Depth Measurement
The evaluation of the implantation process was performed by measuring the mean probe depth. The mean probe depth determined by ultrasound imaging was 1.8 AE 0.1 mm (n 5) (between 1.6 and 2.1 mm), demonstrating the reproducibility of the implantation procedure.
This method con®rmed the sc implantation of the probe just below the smooth skeletal muscle layer which separates the hypoderm from the sc tissue.
In Vivo Calibration of the Microdialysis Probe by the Retrodialysis Method
Because an in vitro determination of recovery may only provide a crude estimate of the behavior of a microdialysis probe, extrapolating such a value to an in vivo experiment is impossible because the nature of the tissue to be sampled and its interactions with the analyte affect the recovery. 20 A dialysis membrane of 20 mm length resulted in an in vivo loss by retrodialysis value of approximately 70% (Table 1) . Loss by retrodialysis determined in vivo was slightly higher for ¯urbiprofen (71.5 AE 0.9% with three probes) than naproxen (71.0 AE 0.8% with three probes), but the difference was not signi®cant (p 0.67). A higher recovery could be obtained by increasing the length of the dialysis ®ber. But, as reported by Yang et al., 3 it is preferable to have a recovery value between 50 and 70%, which permits determining the recovery with a higher precision and accuracy. When the recovery approaches 100%, concentration of the retrodialysis marker in the microdialysate becomes too small for accurate and reproducible HPLC analysis. Because no signi®cant difference was demonstrated between the in vivo loss of naproxen and¯urbi-profen, the in vivo retrodialysis data for naproxen were used to convert dialysate concentrations of urbiprofen into unbound concentrations.
Microdialysis Sampling After ip Administration
To evaluate the potential of sc microdialysis sampling and to investigate the behavior of the probe in terms of dialysis ef®ciency during 8 h of experiment, a pharmacokinetic study with simultaneous sc microdialysis and blood sampling was performed. The results of this study demonstrate the applicability of the manufactured probes, implanted in the sc tissue of the dorsal region of the rat for the characterization of the pharmacokinetics of unbound¯urbiprofen after ip administration of a single dose of 20 mg/kg. Figure 2 shows the average semi-logarithmic concentration±time pro®les for total¯urbiprofen in plasma and unbound¯urbiprofen in the sc extracellular space in four rats. This graph clearly illustrates that sc microdialysis sampling allows the characterization of the unbound concentration±time curve with a discriminating resolution. The difference in scale between the unbound concentration and total concentration is easily understandable by the high protein binding of urbiprofen (b 99.5% at low concentrations). The in vivo loss of the retrodialysis marker during the pharmacokinetic studies was also used to monitor the integrity of the microdialysis probe. In the experiments after ip administration, in vivo loss of naproxen was 62.1 AE 0.6% (n 170). The interindividual coef®cient of variation was lower than 10% (7.4% for four different rats). These results demonstrate a relatively constant dialysis ef®ciency of the probes after implantation and during all the experiments (Fig. 2) .
The unbound concentration of¯urbiprofen in sc tissue versus time shows a short equilibration phase with a t max of 22.9 AE 2.3 min. The total plasma concentration±time curve is characterized by such a rapid absorption phase that the curve is very similar to those observed after iv injection. Pharmacokinetic parameters are summarized in Table 2 . Figure 3 shows the mean semi-logarithmic concentration±time pro®les for total¯urbiprofen in plasma and unbound¯urbiprofen in the sc extracellular space in ®ve rats after iv administration (20 mg/kg) with simultaneous microdialysis and blood sampling. The unbound concentration±time curve shows a rapid equilibration phase with a t max of 15.7 AE 1.1 min. The t max determined after ip was signi®cantly longer than the t max observed after iv (p 0.043, MannWhitney nonparametric test).
Microdialysis Sampling After iv Administration
The in vivo loss of the retrodialysis marker during the pharmacokinetic studies was also used to monitor the integrity of the microdialysis probe. In the experiments after iv administration, in vivo loss of naproxen was 63.4 AE 0.5% (n 188). The interindividual coef®cient of variation was lower than 5% (3.5% for ®ve different rats). These results demonstrate a relatively constant dialysis ef®ciency of the probes after implantation and during all the experiments (Fig. 3) . No signi®cant difference between in vivo loss of naproxen after ip and iv administration was observed (p 0.089).
As reported previously by Evrard et al., 21 the terminal half-life of¯urbiprofen was somewhat longer (p 0.066; paired t test) when considering total¯urbiprofen concentrations (5.8 AE 0.5 h) as compared with unbound concentrations of¯urbi-profen (3.8 AE 0.7 h). The concentration-dependent plasma binding of¯urbiprofen may explain this difference. A similar effect of concentrationdependent plasma protein binding on the apparent half-life was demonstrated for disopyramide. 22 However, after ip administration, this observation concerning the terminal half-life was not con®rmed. The change in the unbound fraction which occurred around the total plasma concentration of 20 mg/mL could explain the in¯ection point of the unbound concentration± time curve. The slope of the curve decreases when the unbound fraction decreases, demonstrating that the transfer and elimination processes occur as a function of the unbound drug. 23 Pharmacokinetic parameters calculated from sc microdialysis experiments are in good agreement with those determined by using iv microdialysis sampling. 21 For one of the four rats after ip administration, the AUC value was markedly smaller (124.0 mg h mL À1 versus 278.0, 245.9, and 200.1 mg h mL À1 ) without being a statistical outlier. This may explain the relatively low value of 0.722 for the ip bioavailability, although there was no signi®cant difference between pharmacokinetic parameters determined after ip and iv administration. Table 2 summarizes the pharmacokinetic parameters.
In Vivo Determination of the Protein Binding
Because only unbound drug molecules pass through the dialysis membrane, microdialysis was shown to be a powerful tool to study the protein binding of drugs in vitro 24, 25 and in vivo. 26, 27 An iv microdialysis study showed that plasma protein binding of¯urbiprofen is concentration-dependent in the rat, even after the administration of a single iv bolus dose of 20 mg/kg. 21 The ratio of unbound to total plasma concentrations of¯urbiprofen, obtained from the experiments with simultaneous sc microdialysis and blood sampling, was not constant but increased with increasing total¯urbiprofen plasma concentration (Fig. 4) . The percentage of the ratio of unbound to total plasma concentrations of¯urbi-profen is relatively constant at total plasma concentrations lower than 20 mg/mL with values around 0.4%. The in vivo unbound fraction, expressed as percent, increases after a sigmoidal relationship when total plasma concentration approaches the concentration of the available binding sites to reach values between 1.0 and 1.5% at a total concentration of 50 mg/mL. 28 This concentration-dependent plasma binding was also demonstrated in vitro by using equilibrium dialysis. The unbound fraction of¯urbiprofen, determined in vitro, was approximately 0.2% at a total concentration of 5 mg/mL and linearly increased to reach a value of approximately 0.8% at a total concentration of 60 mg/mL. The unbound fraction of¯urbiprofen as determined in vitro was lower than the unbound fraction derived from the simultaneous microdialysis and blood sampling experiments. This difference is easily explained by errors inherent to the in vitro technique used 29 but also by the lack of potential competition between metabolites and the parent compounds for the binding proteins. The binding isotherms from in vivo experiments are in good agreement with those reported by Evrard et al. 21 For in vivo data, the best ®t was obtained by using a one binding site model with a non-saturable term (Fig. 5) . The binding parameters of¯urbiprofen, B max , and K d determined by nonlinear least square regression were respectively 20.2 AE 2.7 and 0.03 AE 0.01 mg/mL with a non-saturable term equal to 39.8 AE 5.4 (n 9). The concentrationdependent binding of¯urbiprofen could also explain the observed non-parallelism between the total¯urbiprofen plasma concentrations and the unbound¯urbiprofen sc concentrations (Fig. 3 ). Our results demonstrate that the in vivo plasma protein binding of¯urbiprofen can be determined by sc microdialysis sampling. Very similar fu values were found in this study compared with the fu values reported by Evrard et al. 21 by using the same approach with iv microdialysis sampling. Evrard et al. 21 fully validated iv microdialysis sampling with simultaneous blood sampling as a method to determine the unbound fraction of¯urbiprofen in the circulation. Because sc implantation of the microdialysis probe in the rat is much easier than iv implantation, sc microdialysis sampling offers a much simpler approach to measure in vivo 
CONCLUSIONS
In the ®eld of pharmacokinetics, one of the advantages of microdialysis sampling is to provide concentration±time pro®les with a high temporal resolution. Because it is relatively easily accessible, sc tissue is an attractive sampling site. Therefore, we developed an sc microdialysis sampling technique to study the pharmacokinetics of¯urbiprofen following ip and iv administration. Based on experiments with a simultaneous microdialysis and blood sampling, concentration-dependent protein binding of¯ur-biprofen was demonstrated. Pharmacokinetic parameters and fu values calculated from sc microdialysis experiments are in good agreement with those determined by using the iv microdialysis technique. 21 These results constitute indirect evidence that the unbound concentrations of urbiprofen in the sc compartment are very similar to those in the central compartment. An important advantage of sc microdialysis compared with iv microdialysis is that the implantation of the probe is much more convenient and faster.
